Dyslipidemia
Also known as: high cholesterol · HLD · hypercholesterolemia · hyperlipidemia · lipid management
Sign in to bookmark this disease and track your study progress.
2018 AHA/ACC Guideline on the Management of Blood Cholesterol
AHA/ACC (multisociety) · 2018
The current US cholesterol guideline. It emphasizes lifetime ASCVD-risk reduction and more intensive LDL-C lowering than the 2013 guideline it replaced.
- Uses the Pooled Cohort Equations to estimate 10-year ASCVD risk in primary prevention. source
- Recommends high-intensity or maximally tolerated statins to lower LDL-C by ≥50% in clinical ASCVD. source
- Adds selective use of nonstatin agents (ezetimibe, PCSK9 inhibitors) for very-high-risk patients. source
2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias
ESC/EAS · 2025 · 2025 Focused Update
Supersedes the 2019 ESC/EAS version
The current European dyslipidaemia guidance — a 2025 focused update of the 2019 ESC/EAS guideline, incorporating newer trial evidence on lipid lowering.
US vs EU key differences
- Version currency differs sharply: the US guideline dates to 2018, while the European guidance was refreshed by a 2025 focused update. source
- Risk-estimation tools differ: the US uses the Pooled Cohort Equations, the ESC uses SCORE2 / SCORE2-OP. source
- Both prioritize statins first-line and add nonstatin agents (ezetimibe, PCSK9 inhibitors) for higher-risk patients, but the ESC frames treatment around explicit numeric LDL-C targets. source
What changed recently
- EU2019 → 2025 Focused Update2025-06-15
2025 focused update of the 2019 ESC/EAS guideline, incorporating newer lipid-lowering trial evidence while retaining risk-based LDL-C goals.
See the full update feed for changes across every system.